Template:Isosorbide mononitrate: Difference between revisions

Jump to navigation Jump to search
(Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; ! style="padding: 0 5px; font-size: 100%; background:#F8F8...")
 
No edit summary
 
(2 intermediate revisions by the same user not shown)
Line 2: Line 2:
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Isosorbide mononitrate|{{fontcolor|#6C7B8B|Isosorbide mononitrate}}]]'''''
! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Isosorbide mononitrate|{{fontcolor|#6C7B8B|Isosorbide mononitrate}}]]'''''
|-
|-
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ZZZZZ<sup>®</sup> FDA Package Insert
! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ISOSORBIDE MONONITRATE tablet<sup>®</sup> FDA Package Insert
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide mononitrate indications and usage|Indications and Usage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide mononitrate indications and usage|Indications and Usage]]
Line 17: Line 17:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide mononitrate drug interactions|Drug Interactions]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide mononitrate drug interactions|Drug Interactions]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide mononitrate use in specific populations|Use in Specific Populations]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide mononitrate overdosage|Overdosage]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide mononitrate overdosage|Overdosage]]
Line 25: Line 23:
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide mononitrate clinical pharmacology|Clinical Pharmacology]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide mononitrate clinical pharmacology|Clinical Pharmacology]]
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide mononitrate nonclinical toxicology|Nonclinical Toxicology]]
|-
|-
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide mononitrate clinical studies|Clinical Studies]]
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide mononitrate clinical studies|Clinical Studies]]

Latest revision as of 03:09, 31 January 2014